论文部分内容阅读
目的分析血浆VEGF MIC-1联合尿LAP在2型糖尿病肾病检测中的临床意义,为2型糖尿病肾病患者的早期诊断提供新的思路及理论支持。方法选取2013年4月—2015年6月接收的41例2型糖尿病肾病患者作为实验组,另选取41例同期体检健康者作为健康组,对两组研究对象血液样本及尿液进行检测,对比观察两组研究对象血浆VEGF、MIC-1、尿LAP、肌酐、葡萄糖、尿素、CIM-1及GHb Alc水平。结果实验组血浆VEGF、MIC-1、尿LAP水平分别为(257.11±53.71)pg/ml、(3039.31±1027.12)pg/ml、(53.04±4.53)U/g Gr,而健康组各项指标水平分别为(18.89±5.51)pg/ml、(711.77±311.23)pg/ml、(32.23±5.22)U/g Gr,两组对比差异有统计学意义(P<0.05);实验组肌酐、葡萄糖、尿素、CIM-1及GHb Alc水平均明显高于健康组,差异有统计学意义(P<0.05)。结论可将血浆VEGF MIC-1及尿LAP作为诊断2型糖尿病肾病的检测指标,具有重要临床价值,值得推广运用。
Objective To analyze the clinical significance of plasma VEGF MIC-1 combined with urinary LAP in the detection of type 2 diabetic nephropathy and to provide new ideas and theoretical support for the early diagnosis of type 2 diabetic nephropathy. Methods Forty-one patients with type 2 diabetic nephropathy received from April 2013 to June 2015 were selected as the experimental group. Another 41 healthy people were selected as the healthy group, and the blood samples and urine of the two groups were tested. The levels of plasma VEGF, MIC-1, urinary LAP, creatinine, glucose, urea, CIM-1 and GHb Alc in the two groups were observed. Results The levels of VEGF, MIC-1 and urine LAP in the experimental group were (257.11 ± 53.71) pg / ml, (3039.31 ± 1027.12) pg / ml and (53.04 ± 4.53) U / (P <0.05). The levels of creatinine, glucose, creatinine and creatinine in the experimental group were significantly higher than those in the experimental group (18.89 ± 5.51 pg / ml, (711.77 ± 311.23) pg / ml and (32.23 ± 5.22) Urea, CIM-1 and GHb Alc levels were significantly higher than the healthy group, the difference was statistically significant (P <0.05). Conclusion Plasma VEGF MIC-1 and urine LAP can be used as a diagnostic index in the diagnosis of type 2 diabetic nephropathy, which has important clinical value and is worth promoting.